[go: up one dir, main page]

MX2023013082A - Inhibidores alostéricos de cromenona de la fosfoinosítido 3-quinasa (pi3k) para el tratamiento de enfermedades. - Google Patents

Inhibidores alostéricos de cromenona de la fosfoinosítido 3-quinasa (pi3k) para el tratamiento de enfermedades.

Info

Publication number
MX2023013082A
MX2023013082A MX2023013082A MX2023013082A MX2023013082A MX 2023013082 A MX2023013082 A MX 2023013082A MX 2023013082 A MX2023013082 A MX 2023013082A MX 2023013082 A MX2023013082 A MX 2023013082A MX 2023013082 A MX2023013082 A MX 2023013082A
Authority
MX
Mexico
Prior art keywords
sub
pi3k
chromenone
phosphoinositide
allosteric
Prior art date
Application number
MX2023013082A
Other languages
English (en)
Inventor
Eugene R Hickey
Gabrielle R Kolakowski
Manoj Kumar
Edward A Kesicki
Tien Widjaja
Erin Danielle Anderson
Sean Douglas Aronow
Nicholas A Boyles
Thomas Combs Irvin
Jennifer Lynn Knight
Katelyn Frances Long
Christopher Glenn Mayne
Xiaohong Chen
Surendra Dawadi
Alfredo Picado
Gerit Maria Pototschnig
Hua - Yu WANG
Michael Brian Welch
Nathan Edward Wright
Original Assignee
Petra Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Petra Pharma Corp filed Critical Petra Pharma Corp
Publication of MX2023013082A publication Critical patent/MX2023013082A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Epidemiology (AREA)

Abstract

La descripción se relaciona con compuestos de la Fórmula (I) como inhibidores alostéricos de cromenona de la fosfoinosítido 3-quinasa (PI3K) útiles en el tratamiento de enfermedades o trastornos asociados con la modulación de la PI3K, Fórmula (I): (VER FORMULA I) o sales farmacéuticamente aceptables de estos, en donde R, R1, R2, R3, R4, R5, R6, R7, y R8, son como se definen en la presente descripción. La descripción también se refiere a métodos para preparar y usar los compuestos de Fórmula (I) o sales farmacéuticamente aceptables de los mismos.
MX2023013082A 2021-05-03 2022-05-02 Inhibidores alostéricos de cromenona de la fosfoinosítido 3-quinasa (pi3k) para el tratamiento de enfermedades. MX2023013082A (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US202163183366P 2021-05-03 2021-05-03
US202163227652P 2021-07-30 2021-07-30
US202163250564P 2021-09-30 2021-09-30
US202163253282P 2021-10-07 2021-10-07
US202163253412P 2021-10-07 2021-10-07
PCT/US2022/027306 WO2022235575A1 (en) 2021-05-03 2022-05-02 Allosteric chromenone inhibitors of phosphoinositide 3-kinase (pi3k) for the treatment of disease

Publications (1)

Publication Number Publication Date
MX2023013082A true MX2023013082A (es) 2024-01-08

Family

ID=81748709

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023013082A MX2023013082A (es) 2021-05-03 2022-05-02 Inhibidores alostéricos de cromenona de la fosfoinosítido 3-quinasa (pi3k) para el tratamiento de enfermedades.

Country Status (11)

Country Link
US (2) US20230014445A1 (es)
EP (1) EP4334312A1 (es)
JP (2) JP7759964B2 (es)
KR (1) KR20240004744A (es)
AU (1) AU2022269566B2 (es)
BR (1) BR112023022580A2 (es)
CA (1) CA3216800A1 (es)
IL (1) IL308191A (es)
MX (1) MX2023013082A (es)
TW (1) TW202309011A (es)
WO (1) WO2022235575A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112023022940A2 (pt) 2021-05-03 2024-01-23 Petra Pharma Corp Inibidores alostéricos de cromenona de fosfoinositídeo 3-quinase (pi3k) para o tratamento de doenças
IL308776A (en) 2021-05-27 2024-01-01 Petra Pharma Corp Allosteric chromenone inhibitors of phosphoinositide 3-kinase (pi3k) for the treatment of cancer
TW202329930A (zh) * 2021-09-30 2023-08-01 美商佩特拉製藥公司 用於治療疾病之磷酸肌醇3-激酶(pi3k)之異位色烯酮抑制劑
WO2023081209A1 (en) * 2021-11-03 2023-05-11 Zeno Management, Inc. Pi3k inhibitors and methods of treating cancer
CA3237760A1 (en) * 2021-12-08 2023-06-15 Xiaolin Hao Fused heterocyclic compounds as pi3kalpha inhibitors
CN119095846A (zh) * 2022-04-24 2024-12-06 益方生物科技(上海)股份有限公司 化合物、其制备方法和用途
AU2023259406A1 (en) * 2022-04-29 2024-09-26 Petra Pharma Corporation Allosteric chromenone inhibitors of phosphoinositide 3-kinase (pi3k) for the treatment of disease
CN120500334A (zh) 2022-11-02 2025-08-15 佩特拉制药公司 靶向磷酸肌醇3-激酶(pi3k)的变构和正构口袋以用于治疗疾病
CN117186093B (zh) * 2022-12-15 2025-12-12 苏州浦合医药科技有限公司 PI3Kα变构抑制剂
EP4646271A1 (en) * 2023-01-06 2025-11-12 Mirati Therapeutics, Inc. Substituted spirocyclic-pyrroloquinazolinones and spirocyclic-piperidinoquinazolinones
WO2024211346A1 (en) * 2023-04-03 2024-10-10 Prelude Therapeutics Incorporated Mutant pi3k-alpha inhibitors and their use as pharmaceuticals
AU2024268541A1 (en) 2023-05-05 2025-11-20 Eli Lilly And Company Imlunestrant or salts thereof for use in treating and preventing central nervous system (cns) metastases in subjects having er+ breast cancer
CN119431297A (zh) * 2023-08-02 2025-02-14 郑州同源康医药有限公司 稠环类化合物及其用途
WO2025051235A1 (en) * 2023-09-07 2025-03-13 InventisBio Co., Ltd. Compounds, preparation methods and uses thereof
CN119874676A (zh) * 2023-10-25 2025-04-25 海创药业股份有限公司 一种pi3k抑制剂及其制备方法和用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2495661C (en) * 2002-08-16 2011-06-14 Kinacia Pty Ltd. Inhibition of phosphoinositide 3-kinase beta
US8399460B2 (en) * 2009-10-27 2013-03-19 Astrazeneca Ab Chromenone derivatives
AR121719A1 (es) * 2020-04-03 2022-06-29 Petra Pharma Corp Inhibidores alostéricos de cromenona del fosfoinosítido 3-quinasa (pi3k) para el tratamiento de enfermedades
BR112023022940A2 (pt) * 2021-05-03 2024-01-23 Petra Pharma Corp Inibidores alostéricos de cromenona de fosfoinositídeo 3-quinase (pi3k) para o tratamento de doenças

Also Published As

Publication number Publication date
EP4334312A1 (en) 2024-03-13
JP7759964B2 (ja) 2025-10-24
BR112023022580A2 (pt) 2024-01-09
TW202309011A (zh) 2023-03-01
US20230014445A1 (en) 2023-01-19
KR20240004744A (ko) 2024-01-11
CA3216800A1 (en) 2022-11-10
AU2022269566A1 (en) 2023-11-02
US20240383878A1 (en) 2024-11-21
JP2024516993A (ja) 2024-04-18
IL308191A (en) 2024-01-01
JP2026004333A (ja) 2026-01-14
AU2022269566B2 (en) 2024-12-12
WO2022235575A1 (en) 2022-11-10

Similar Documents

Publication Publication Date Title
MX2023013082A (es) Inhibidores alostéricos de cromenona de la fosfoinosítido 3-quinasa (pi3k) para el tratamiento de enfermedades.
MX2023013080A (es) Inhibidores alostericos de cromenona del fosfoinositido 3-quinasa (pi3k) para el tratamiento de enfermedades.
MX2024013178A (es) Inhibidores alostericos de cromenona de la fosfoinositido 3-quinasa (pi3k) para el tratamiento de enfermedades
MX2022012306A (es) Inhibidores alostericos de cromenona del fosfoinositido 3-quinasa (pi3k) para el tratamiento de enfermedades.
SA523451700B1 (ar) (pi3k) مثبطات الكرومينون الألستيرية للفوسفونوسيتيد 3-كيناز لعلاج السرطان
MX2022013482A (es) Compuestos utiles para inhibir la quinasa ret.
CR20230310A (es) Inhibidores de prmt5
MX2023009222A (es) Inhibidores tricíclicos-amido-bicíclicos de prmt5.
MX2009005950A (es) Compuestos inhibidores de fosfoinositido 3-quinasas y metodos de uso.
MX2009005925A (es) Compuestos inhibidores de fosfoinositida 3-quinasa y los metodos de uso.
GB0112348D0 (en) Compounds
SE0202462D0 (sv) Novel use
TW200801012A (en) Phosphoinositide 3-kinase inhibitor compounds and methods of use
TW200613306A (en) Imidazotriazines as protein kinase inhibitors
MX338504B (es) Combinaciones de compuestos inhibidores de fosfoinosituro 3-cinasa y agentes quimioterapeuticos, y metodos de uso.
EA201071232A1 (ru) Триазины как ингибиторы киназы pi3 и mtor
MXPA05010958A (es) Derivados indazol como inhibidores jnk.
NO331166B1 (no) Inhibitorer av tyrosinkinaser, fremgangsmate for fremstilling derav, farmasoytisk preparat samt anvendelse av forbindelsene
NO20082508L (no) Aminopyrimidiner anvendelige som kinaseinhibitorer
EA202091450A1 (ru) Производные 2h-индазола в качестве ингибиторов cdk4 и cdk6 и их терапевтические применения
SE0202429D0 (sv) Novel Compounds
EA202192900A1 (ru) Модуляторы пути интегрированной реакции на стресс
MX2024014626A (es) Metodos de tratamiento de la urticaria cronica espontanea utilizando un inhibidor de la tirosina quinasa de bruton
ATE357453T1 (de) Comt-inhibitoren
AU2020278236A8 (en) Methods of treating Sjögren's Syndrome using a Bruton's tyrosine kinase inhibitor